1-3 of 3
Ritul Sharma
Close
Sort by
Journal Articles

Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

Ritul Sharma, Melanie M Frigault, Amy J Johnson, Raquel Izumi, Ahmed Hamdy, Joseph Birkett, Beatrix Stelte-Ludwig, Luke Maese, Norman J. Lacayo, Aru Narendran
Journal: Blood
Blood (2023) 142 (Supplement 1): 4293.
https://doi.org/10.1182/blood-2023-180567
Published: 2023
Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran
Journal: Blood
Blood (2022) 140 (Supplement 1): 10685–10686.
https://doi.org/10.1182/blood-2022-169917
Published: 2022
Journal Articles

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Chunfen Zhang, MD, Ritul Sharma, MSc., Thakur Satbir, PhD, Allison Cheney, Olena Vaske, PhD, Lauren Sanders, Jessica Boklan, MD, Victor A. Lewis, MD, Ronald Anderson, MDFRCPC, Olga Kovalchuk, MD, PhD, Norman J. Lacayo, MD, Aru Narendran, MD PhD, Kevin J. Bielamowicz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2633.
https://doi.org/10.1182/blood-2019-131444
Published: 2019